This qualitative interview study (n=6 out of 13) on MDMA-assisted therapy for end-of-life anxiety, conducted three months after dosing (3x 125mg), highlights the psychological processes participants went through. Treatment outcomes included better management of medical symptoms and relationship to illness, reduction in psychological symptoms, improved quality of life, being more present, and feeling more resourced.
Abstract
“Anxiety associated with life-threatening illness (LTI) is a pervasive mental health issue with a wide impact. A spectrum of traditional pharmacotherapies and psychotherapies are available, but offer varying success in reducing symptoms and improving quality of life. We explore a novel therapy for this condition by assessing prominent thematic elements from participant narrative accounts of a pilot phase 2 clinical trial of 3,4 Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT) for treating anxiety associated with LTI. Semi-structured qualitative interviews were conducted with a subset of adult participants 3 months following completion of this trial. This qualitative analysis sought to complement, clarify, and expand upon the quantitative findings obtained from the clinical trial to further understand the process and outcomes of the treatment. Interviews were coded and analyzed using an Interpretative Phenomenological Analysis (IPA) methodological framework. Participants described in detail their experiences from before, during and after the trial, which were analyzed and categorized into thematic clusters. Specifically, participants explored what they felt were important elements of the therapeutic process including processing trauma and grief, exploring mystical and existential experiences, engaging with the present moment with reduced physiological activation, and facing illness and existential fears. Outcomes of the treatment included increased ability to cope with LTI, reduced psychological symptoms, improved vitality and quality of life, and feeling more resourced. Participant narratives also showed a reconnection to life and greater emotional resilience in response to trauma and medical relapse. These findings are compared to similar treatments for the same indication. Limitations and challenges encountered in conducting this study are discussed along with implications for theory and clinical treatment.”
Authors: William Barone, Michiko Mitsunaga-Whitten, Lia O. Blaustein, Phillip Perl, Marisa Swank & Thomas C. Swift
Find this paper
https://doi.org/10.1038/s41598-020-75706-1
Open Access | Google Scholar | Backup | 🕊
Compound Details
The psychedelics given at which dose and how many times
MDMA 100 - 125mg | 3x
Linked Research Papers
Notable research papers that build on or are influenced by this paper
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot studyThis double-blind, placebo-controlled study (n=18) with MDMA (125mg, 2-3 sessions) in combination with psychotherapy found no significant difference in anxiety in a population with life-threatening illnesses. Though no significant group difference was found (p=.056), the study showed a large effect size (g=1.03) and a larger sample size might find a significant difference (favouring MDMA).
Linked Clinical Trial
MDMA-assisted Psychotherapy for Anxiety Associated With a Life-threatening IllnessThis Phase 2 pilot study is a randomized, double-blind, placebo-controlled study in 18 participants comparing the effects of MDMA-assisted therapy vs. placebo with therapy.